Redhill Biopharma Ltd. (NASDAQ:RDHL) Short Interest Update

Redhill Biopharma Ltd. (NASDAQ:RDHL) saw a large decline in short interest during the month of February. As of February 27th, there was short interest totaling 28,626 shares, a decline of 13.6% from the February 12th total of 33,139 shares. Approximately 0.6% of the shares of the company are short sold. Based on an average daily volume of 36,555 shares, the short-interest ratio is presently 0.8 days. Based on an average daily volume of 36,555 shares, the short-interest ratio is presently 0.8 days. Approximately 0.6% of the shares of the company are short sold.

Redhill Biopharma Stock Down 3.5%

RDHL opened at $0.84 on Thursday. The firm’s fifty day simple moving average is $1.08 and its two-hundred day simple moving average is $1.28. Redhill Biopharma has a 52-week low of $0.80 and a 52-week high of $3.31. The company has a market cap of $4.32 million, a price-to-earnings ratio of 0.00 and a beta of 4.91.

Institutional Investors Weigh In On Redhill Biopharma

A hedge fund recently raised its stake in Redhill Biopharma stock. Gagnon Securities LLC grew its position in Redhill Biopharma Ltd. (NASDAQ:RDHL) by 383.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 86,102 shares of the biotechnology company’s stock after acquiring an additional 68,280 shares during the quarter. Gagnon Securities LLC owned about 1.68% of Redhill Biopharma worth $89,000 as of its most recent SEC filing. Institutional investors own 7.20% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Redhill Biopharma in a report on Thursday, January 22nd. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has an average rating of “Sell”.

Redhill Biopharma Company Profile

RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered small molecules for the treatment of inflammatory, gastrointestinal and oncology indications. Founded in 2009 and headquartered in Tel Aviv, Israel, RedHill is publicly traded on the Nasdaq under the symbol RDHL. The company’s strategy centers on in-licensing late-stage clinical candidates and advancing them through regulatory review toward global commercialization.

RedHill’s lead marketed product, Talicia® (formerly RHB-105), is an FDA-approved, three-drug treatment for Helicobacter pylori infection, co-commercialized in the United States through a partnership with Bausch Health.